Pankit Vachhani, MD

A brief overview of myeloproliferative neoplasms and the associated signs and symptoms commonly presenting in patients.

Closing out their discussion on myelofibrosis, experts provide practical advice for identifying and managing patients in real-world practice.

Focusing on novel combination strategies, experts review clinical trial data and consider where these regimens may fall in the myelofibrosis treatment armamentarium.

A comprehensive review of novel agents currently under investigation with a potential role in the myelofibrosis treatment landscape.

Expert perspectives on monitoring patients receiving therapy for myelofibrosis, with additional considerations for when it is appropriate to switch therapy.

Taking into account the three JAK inhibitors, ruxolitinib, fedratinib, and pacritinib, experts reflect on the appropriate use of each agent in myelofibrosis.

Shared insight on the respective roles of fedratinib and pacritinib in patients diagnosed with myelofibrosis.

Expert perspectives on the role of ruxolitinib in patients who require systemic therapy for myelofibrosis.

A brief review of the historical use of systemic therapy in patients who present with myelofibrosis.

Stephen Oh, MD, PhD, highlights the role of transplant in myelofibrosis before Ruben Mesa, MD, discusses factors in selecting systemic therapy.

Expert Pankit Vachhani, MD, breaks down best practices in observation and dictates when it is best to initiated therapy for myelofibrosis.

Experts focus on how best to risk stratify and stage myelofibrosis using appropriate diagnostic tools and workup.

Reflections on the predominant challenges one may face while making a differential diagnosis of myelofibrosis.

Shared insight on the differential diagnosis of myelofibrosis, including advice for identifying primary versus secondary disease.

A brief discussion on the role of ruxolitinib in the management of polycythemia vera, followed by a review of goals of therapy in this setting.

Pankit Vachhani, MD, provides a comprehensive overview of approved agents used to manage patients with polycythemia vera.

Shared insight on making a differential diagnosis of polycythemia vera and properly risk-stratifying patients who present with this disease.

Expert Stephen Oh, MD, PhD, provides a broad overview of the myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis.

Pankit Vachhani, MD, reacts to treatment limitations for health care professionals who care for patients with myeloproliferative neoplasms.

Patient factors and disease characteristics that impact decisions to treat patients with myelofibrosis with ruxolitinib or fedratinib.

Pankit Vachhani, MD, explains how to properly treat myelofibrosis using ruxolitinib based on data provided by key clinical trials like COMFORT-I and COMFORT-II.

Criteria and assessments that can be used to help clinicians select treatment and monitor patients on therapy for myelofibrosis.

Pankit Vachhani, MD, comments on goals of therapy for patients with myelofibrosis and highlights traditional treatment approaches.

An overview of risk stratification models available to assess and classify patients with primary myelofibrosis.

Expert panelists review important disease-related and patient-related factors when considering bone marrow transplant in patients with primary myelofibrosis.

Pankit Vachhani, MD, guides a discussion on the FDA approval of fedratinib and reviews how it has affected the therapeutic landscape for patients with primary myelofibrosis.

MPN expert Srdan Verstovsek, MD, PhD, shares insights into the role of ruxolitinib for the treatment of myelofibrosis.

An expert in the management of myeloproliferative neoplasms, Jamile Shammo, MD, FASCP, FACP, leads a discussion on best practices for assessing response and monitoring for progression.

Pankit Vachhani, MD, reviews recent changes to the NCCN Guidelines, highlighting the addition of luspatercept for the treatment of primary myelofibrosis.

Key opinion leaders in the management of myeloproliferative neoplasms review factors to consider when selecting treatments for patients and highlight the role of fedratinib in the first- or second-line settings.